JP2019513395A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513395A5
JP2019513395A5 JP2018554006A JP2018554006A JP2019513395A5 JP 2019513395 A5 JP2019513395 A5 JP 2019513395A5 JP 2018554006 A JP2018554006 A JP 2018554006A JP 2018554006 A JP2018554006 A JP 2018554006A JP 2019513395 A5 JP2019513395 A5 JP 2019513395A5
Authority
JP
Japan
Prior art keywords
seq
sequence
nucleic acid
effector
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554006A
Other languages
English (en)
Japanese (ja)
Other versions
JP7236195B2 (ja
JP2019513395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050330 external-priority patent/WO2017177277A1/en
Publication of JP2019513395A publication Critical patent/JP2019513395A/ja
Publication of JP2019513395A5 publication Critical patent/JP2019513395A5/ja
Application granted granted Critical
Publication of JP7236195B2 publication Critical patent/JP7236195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554006A 2016-04-14 2017-04-13 眼咽頭筋ジストロフィー(opmd)の処置のための試薬およびその使用 Active JP7236195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322745P 2016-04-14 2016-04-14
US62/322,745 2016-04-14
PCT/AU2017/050330 WO2017177277A1 (en) 2016-04-14 2017-04-13 Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof

Publications (3)

Publication Number Publication Date
JP2019513395A JP2019513395A (ja) 2019-05-30
JP2019513395A5 true JP2019513395A5 (enExample) 2020-04-23
JP7236195B2 JP7236195B2 (ja) 2023-03-09

Family

ID=60041243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554006A Active JP7236195B2 (ja) 2016-04-14 2017-04-13 眼咽頭筋ジストロフィー(opmd)の処置のための試薬およびその使用

Country Status (14)

Country Link
US (1) US11234994B2 (enExample)
EP (1) EP3443091A4 (enExample)
JP (1) JP7236195B2 (enExample)
KR (1) KR102353847B1 (enExample)
CN (1) CN109219659B (enExample)
AU (1) AU2017250017B2 (enExample)
CA (1) CA3020754C (enExample)
IL (1) IL262337B2 (enExample)
MX (1) MX2018012545A (enExample)
NZ (1) NZ747314A (enExample)
RU (1) RU2755544C2 (enExample)
SG (1) SG11201808981XA (enExample)
WO (1) WO2017177277A1 (enExample)
ZA (1) ZA201807589B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2755544C2 (ru) 2016-04-14 2021-09-17 Бенитек Биофарма Лимитед Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение
EP3555294A4 (en) 2016-12-14 2020-08-26 Benitec Biopharma Limited REAGENTS FOR THE TREATMENT OF OCULOPHARYNGEAL MUSCLE DYSTROPHY (PDD) AND THEIR USE
US20220106594A1 (en) * 2018-10-17 2022-04-07 Benitec Biopharma Limited Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
ES2083593T3 (es) 1990-08-03 1996-04-16 Sterling Winthrop Inc Compuestos y metodos para inhibir la expresion de genes.
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
AU6412794A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
JP2002500201A (ja) 1998-01-05 2002-01-08 ユニバーシティ オブ ワシントン 膜破壊剤を使用する増強された輸送
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
WO2001053307A1 (en) 2000-01-21 2001-07-26 Geron Corporation 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use
AU8695901A (en) 2000-09-01 2002-03-13 Ribozyme Pharm Inc Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US7514099B2 (en) 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP2017338A1 (en) 2001-05-24 2009-01-21 Genzyme Corporation Muscle-specific expression vectors
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
JP2008526229A (ja) * 2005-01-06 2008-07-24 ベニテック,インコーポレーテッド 幹細胞の維持のためのRNAi剤
US8110184B2 (en) * 2005-09-30 2012-02-07 University Of Kentucky Research Foundation Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations
EP2014281A1 (en) * 2007-06-19 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
PH12013501410A1 (en) 2010-12-30 2013-08-28 Dow Agrosciences Llc Nucleic acid molecules that target the rho1 small gtp-binding protein and confer resistance to coleopteran pests
KR101454425B1 (ko) * 2012-10-11 2014-11-03 포항공과대학교 산학협력단 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물
WO2014077693A1 (en) 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
KR101683964B1 (ko) * 2014-05-29 2016-12-09 연세대학교 산학협력단 Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터
RU2755544C2 (ru) 2016-04-14 2021-09-17 Бенитек Биофарма Лимитед Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение

Similar Documents

Publication Publication Date Title
EP2633051B1 (en) Hbv treatment
US9518260B2 (en) Pain treatment
CN101603042B (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
JP2005521393A5 (enExample)
JP2022185052A5 (enExample)
JP2025016451A5 (enExample)
JP2010500025A5 (enExample)
JP2020503014A5 (enExample)
AU2021213253A1 (en) Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement
JP2017528441A5 (enExample)
JP2019513395A5 (enExample)
IL267353B1 (en) Reagents for the treatment of oculopharyngeal muscular dystrophy (opmd) and their uses
CN103275971A (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
US9970004B2 (en) Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interferencde in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
RU2018138271A (ru) Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение
JP2007530431A5 (enExample)
JP2019514401A5 (enExample)
JP2026502888A (ja) エピジェネティック調節因子の新規阻害剤
WO2009002918A2 (en) Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use
RU2018142797A (ru) Средства для лечения инфекции вируса гепатита в (hbv) и их применение
JP2008503569A5 (enExample)
US9790502B2 (en) HBV treatment
JPWO2020061528A5 (enExample)
JPWO2020047476A5 (enExample)
JPWO2021020412A5 (enExample)